These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 31832993)

  • 61. Dapsone for acne: Still in use after half a century!
    Searle T; Al-Niaimi F; Ali FR
    J Cosmet Dermatol; 2021 Jul; 20(7):2036-2039. PubMed ID: 33600049
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oral and topical spironolactone therapies in skin androgenization.
    Messina M; Manieri C; Musso MC; Pastorino R
    Panminerva Med; 1990; 32(2):49-55. PubMed ID: 2147469
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature.
    Ocampo-Garza SS; Fabbrocini G; Ocampo-Candiani J; Cinelli E; Villani A
    Dermatol Ther; 2020 Nov; 33(6):e14267. PubMed ID: 32882083
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Microneedling for Hair Loss.
    Gupta AK; Quinlan EM; Venkataraman M; Bamimore MA
    J Cosmet Dermatol; 2022 Jan; 21(1):108-117. PubMed ID: 34714971
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Topical Clascoterone for Acne Vulgaris.
    Burma NE; Woo TE; Parsons L
    Skin Therapy Lett; 2022 Jan; 27(1):1-3. PubMed ID: 35081302
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
    Suchonwanit P; Rojhirunsakool S; Khunkhet S
    Lasers Med Sci; 2019 Dec; 34(9):1857-1864. PubMed ID: 30982177
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia.
    Rossi A; Campo D; Fortuna MC; Garelli V; Pranteda G; De Vita G; Sorriso-Valvo L; Di Nunno D; Carlesimo M
    J Dermatolog Treat; 2018 Mar; 29(2):149-151. PubMed ID: 28604133
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience.
    Sovak M; Seligson AL; Kucerova R; Bienova M; Hajduch M; Bucek M
    Dermatol Surg; 2002 Aug; 28(8):678-85. PubMed ID: 12174057
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
    Azzouni F; Zeitouni N; Mohler J
    J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years.
    Piszczatoski CR; Powell J
    Clin Ther; 2021 Oct; 43(10):1638-1644. PubMed ID: 34607697
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Topical Finasteride: A Comprehensive Review of Androgenetic Alopecia Management for Men and Women.
    Keerti A; Madke B; Keerti A; Lopez MJC; Lirio FS
    Cureus; 2023 Sep; 15(9):e44949. PubMed ID: 37818522
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hormonal therapies for acne.
    Barros B; Thiboutot D
    Clin Dermatol; 2017; 35(2):168-172. PubMed ID: 28274354
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia.
    Galadari H; Shivakumar S; Lotti T; Wollina U; Goren A; Rokni GR; Grabbe S; Goldust M
    Lasers Med Sci; 2020 Aug; 35(6):1239-1244. PubMed ID: 32162134
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia.
    Gupta AK; Talukder M; Williams G
    Expert Opin Emerg Drugs; 2024 Apr; ():1-11. PubMed ID: 38666717
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The use of hormonal agents in the treatment of acne.
    Hassoun LA; Chahal DS; Sivamani RK; Larsen LN
    Semin Cutan Med Surg; 2016 Jun; 35(2):68-73. PubMed ID: 27416311
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Androgenetic alopecia: an update.
    Kaliyadan F; Nambiar A; Vijayaraghavan S
    Indian J Dermatol Venereol Leprol; 2013; 79(5):613-25. PubMed ID: 23974579
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist.
    Kircik LH
    Expert Opin Pharmacother; 2021 Sep; 22(13):1801-1806. PubMed ID: 33906537
    [No Abstract]   [Full Text] [Related]  

  • 78. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
    Olsen EA; Dunlap FE; Funicella T; Koperski JA; Swinehart JM; Tschen EH; Trancik RJ
    J Am Acad Dermatol; 2002 Sep; 47(3):377-85. PubMed ID: 12196747
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study.
    Suchonwanit P; Iamsumang W; Rojhirunsakool S
    Am J Clin Dermatol; 2019 Feb; 20(1):147-153. PubMed ID: 30206824
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution.
    Marotta JC; Patel G; Carvalho M; Blakeney S
    Int J Pharm Compd; 2020; 24(1):69-76. PubMed ID: 32023218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.